Evidence map›Paper›PMID 36162919›Full record

ArticleJournal for immunotherapy of cancer2022

Loss of secreted gelsolin enhances response to anticancer therapies.

Kok Haw Jonathan Lim, Evangelos Giampazolias, Oliver Schulz, Neil C Rogers, Anna Wilkins, Erik Sahai, Jessica Strid, Caetano Reis e Sousa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kok Haw Jonathan LimImmunobiology Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-6544-9218
Evangelos GiampazoliasImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Oliver SchulzImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Neil C RogersImmunobiology Laboratory, The Francis Crick Institute, London, UK.
Anna WilkinsTumour Cell Biology Laboratory, The Francis Crick Institute, London, UK.
Erik SahaiTumour Cell Biology Laboratory, The Francis Crick Institute, London, UK.
Jessica StridDepartment of Immunology and Inflammation, Imperial College London, London, UK.
Caetano Reis e SousaImmunobiology Laboratory, The Francis Crick Institute, London, UK caetano@crick.ac.uk.ORCID 0000-0001-7392-2119
The Francis Crick Institute · GBImperial College London · GBInstitute of Cancer Research · GB

Funding

Cancer Research UK FC001136Wellcome Trust 106973/Z/15/ZWellcome Trust 216327/Z/19/ZWellcome Trust FC001136
6 · The paper itself

Abstract

Type 1 conventional dendritic cells (cDC1) play a critical role in priming anticancer cytotoxic CD8

Indexed as

GelsolinMelanoma, ExperimentalActinsAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesDoxorubicinHomeodomain ProteinsLectins, C-TypeMiceOvalbuminProto-Oncogene Proteins B-rafReceptors, ImmunologicActinsAntigens, NeoplasmDoxorubicinGelsolinHomeodomain ProteinsLectins, C-TypeOvalbuminProto-Oncogene Proteins B-rafReceptors, Immunologicantigen presentationdendritic cellsimmunity

Identifiers

PMID36162919
PMCPMC9516286
OpenAlexW4297141771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.